Viewing data from:

PRIMIDONE

ANDA

PRIMIDONE | A040586 | OXFORD PHARMACEUTICALS LLC

2 strengths0 unique patents0 unique exclusivities

Reference Listed Drug: MYSOLINE(TE code: AB)

Medicare Part D Spending

CMS annual spending data for Primidone (2023)

Total Spending

$40.6M

Total Claims

1,344,964

Beneficiaries

279,909

Avg Cost/Unit

$0.23

Spending Trend

$28.8M(2019)→$30.9M(2020)→$33.9M(2021)→$37.2M(2022)→$40.6M(2023)

YoY Change:+4.4%

5yr CAGR:+3.7%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

API Supply Chain5 active DMFs2 inactive

5 active API suppliers hold Drug Master Files for this ingredient.

SIEGFRIED LTDPRIMIDONE

DMF 21991973

DR REDDYS LABORATORIES LTDPRIMIDONE

DMF 200072006

NANTONG JINGHUA PHARMACEUTICAL CO LTDPRIMIDONE

DMF 216022008

BIOPHORE INDIA PHARMACEUTICALS PVT LTDPRIMIDONE

DMF 352022020

RAKS PHARMA PVT LTDPRIMIDONE USP

DMF 407702024

NANTONG GENERAL PHARMACEUTICAL FACTORYInactivePRIMIDONE USP XXII

DMF 84061990

PROVENTUS LIFE SCIENCES PVT LTDInactivePRIMIDONE

DMF 234442010

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (2)

Sort:

#001 — 50MG

0 patents0 exclusivities▴

TABLET;ORAL | Approved: Feb 24, 2005

No patent or exclusivity listings for this strength.

#002 — 250MG

0 patents0 exclusivities▾

TABLET;ORAL | Approved: Feb 24, 2005